Disease-modifying potential of BET inhibitor pelabresib (CPI-0610) as demonstrated by improvements in bone marrow function and clinical activity in patients with myelofibrosis – preliminary data

Preliminary results from the phase 2 MANIFEST trial show that treatment with pelabresib as monotherapy or in combination with ruxolitinib among both ruxolitinib-naïve and -experienced patients with myelofibrosis suggest the disease-modifying potential of pelabresib through improvement of bone marrow histology and function. Data presented during the 2021 American Society of Hematology Annual Meeting show that ERY progenitors increased in 50% of patients, MK density decreased in 57% of patients, and bone marrow improved after 24 weeks of treatment.